{"id":559647,"date":"2026-06-12T08:00:00","date_gmt":"2026-06-12T06:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/inibidores-orais-altamente-seletivos-da-tyk-em-fase-iii\/"},"modified":"2026-06-18T17:17:01","modified_gmt":"2026-06-18T15:17:01","slug":"inibidores-orais-altamente-seletivos-da-tyk-em-fase-iii","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/inibidores-orais-altamente-seletivos-da-tyk-em-fase-iii\/","title":{"rendered":"Inibidores orais altamente seletivos da TYK em fase III"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>O envudeucitinib e o zasocitinib s\u00e3o inibidores alost\u00e9ricos orais da tirosina quinase 2 (TYK2), que est\u00e3o atualmente a ser estudados em ensaios cl\u00ednicos no \u00e2mbito da psor\u00edase em placas. Os resultados provis\u00f3rios apresentados no \u00e2mbito das sess\u00f5es de investiga\u00e7\u00e3o de \u00faltima hora do congresso anual deste ano da <em>Academia Americana de Dermatologia<\/em> (AAD) chamam a aten\u00e7\u00e3o. \u00c9 igualmente de salientar o perfil de seguran\u00e7a favor\u00e1vel, o que, aliado \u00e0 via de administra\u00e7\u00e3o oral, constitui uma grande vantagem em termos de conveni\u00eancia.    <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Finibidores-orais-altamente-seletivos-da-tyk-em-fase-iii%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>O envudeucitinib e o zasocitinib s\u00e3o inibidores alost\u00e9ricos orais da tirosina quinase 2 (TYK2), que est\u00e3o atualmente a ser estudados em ensaios cl\u00ednicos no \u00e2mbito da psor\u00edase em placas. Os&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Finibidores-orais-altamente-seletivos-da-tyk-em-fase-iii%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":559648,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Investiga\u00e7\u00e3o sobre a psor\u00edase: O que est\u00e1 em fase de desenvolvimento?  ","footnotes":""},"category":[11551,11344,11356,11521,11453,11529,11496],"tags":[21769,95031,95034,95035,95032,95039,95036,95033,13978,95037,95038],"powerkit_post_featured":[],"class_list":["post-559647","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-pt","category-alergologia-e-imunologia-clinica","category-dermatologia-e-venereologia-pt-pt","category-estudos","category-farmacologia-e-toxicologia","category-relatorios-do-congresso","category-reumatologia-pt-pt","tag-aad-pt-pt","tag-academia-americana-de-dermatologia","tag-conveniencia","tag-envudeucitinib","tag-inibidores-da-tyk","tag-latitude-3002","tag-latitude-pso-3001","tag-pipeline","tag-psoriase-pt-pt","tag-resultados-provisorios","tag-zasocitinib","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-27 06:32:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":559650,"slug":"inhibidores-orales-de-tyk-altamente-selectivos-en-fase-iii","post_title":"Inhibidores orales de TYK altamente selectivos en fase III","href":"https:\/\/medizinonline.com\/es\/inhibidores-orales-de-tyk-altamente-selectivos-en-fase-iii\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/559647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=559647"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/559647\/revisions"}],"predecessor-version":[{"id":559649,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/559647\/revisions\/559649"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/559648"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=559647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=559647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=559647"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=559647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}